April 24, 2026 a 07:43 pm
MRK: Fundamental Ratio Analysis - Merck & Co., Inc.
Merck & Co., Inc., a prominent player in the healthcare sector, operates globally in pharmaceutical and animal health segments. Recent evaluations suggest a strong standing in the industry, with promising potential for growth. Its collaborations with major companies like AstraZeneca and Bayer highlight its drive for innovation in medical treatments.
Fundamental Rating
The current ratings for Merck & Co., Inc. display solid performance metrics. The overall score and individual category assessments indicate the company's stable financial health and growth potential.
| Category | Score | Visual |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return on Equity | 5 | |
| Return on Assets | 5 | |
| Debt to Equity | 1 | |
| Price to Earnings | 3 | |
| Price to Book | 2 |
Historical Rating
A retrospective glance at Merck & Co., Inc.'s historical ratings shows consistent performance, underscoring its steady market presence.
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2026-04-24 | 4 | 4 | 5 | 5 | 1 | 3 | 2 |
| Previous | 0 | 4 | 5 | 5 | 1 | 3 | 2 |
Analyst Price Targets
Analysts' price targets for Merck & Co., Inc. offer diverse perspectives. The consensus indicates a positive outlook.
| High | Low | Median | Consensus |
|---|---|---|---|
| $150 | $100 | $133 | $128.54 |
Analyst Sentiment
The sentiment among analysts is predominantly positive, with the majority recommending a 'Buy'.
| Recommendation | Count | Visual |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 25 | |
| Hold | 11 | |
| Sell | 1 | |
| Strong Sell | 0 |
In conclusion, Merck & Co., Inc. showcases robust financial stability and is well-positioned in the healthcare market. Despite challenges within the sector, its ongoing collaborations and sound financial metrics provide a solid foundation for prospective growth. While some areas such as debt management could improve, overall market sentiment remains favorable, supporting a positive outlook for investors.